Anti-CD39 Antibody-Drug Conjugate DAR Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ADC drugs targeting CD39 have limitations in efficacy and safety due to uncertainties in the combination of new antibodies with different linkers and toxins, and there is a clinical need for developing drug molecules with better efficacy.
Innovation Solution
The development of an anti-CD39 antibody-drug conjugate represented by general formula (I), which includes an anti-CD39 antibody or its antigen-binding fragment, a linker, and a cytotoxin molecule, with a specific average conjugation quantity (DAR value) to enhance targeted killing of tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a new anti-CD39 antibody is combined with different linkers and toxins to create ADC drugs, then the potential therapeutic efficacy is improved, but the uncertainty in efficacy and safety increases
Solution Approach 1:
The patent optimizes the drug-to-antibody ratio (DAR) parameter to specific values (3.8-4.2 for cysteine conjugation, 4.8-5.2 for lysine conjugation) to achieve the best balance between efficacy and safety. This parameter optimization resolves the contradiction by identifying specific numerical values that maximize therapeutic effect while minimizing uncertainty
Solution Approach 2:
The patent uses a proven anti-CD39 antibody (F314) as a template and creates multiple ADC variants by copying its structure and systematically varying only the linker-toxin components. This approach reduces uncertainty by maintaining a consistent, validated antibody platform while exploring different linker-toxin combinations
2Productivity
If the conjugation quantity of cytotoxin molecules is increased to enhance killing activity, then the anti-tumor efficacy is improved, but the therapeutic index may deteriorate
Solution Approach 1:
The patent identifies and optimizes the DAR parameter to specific ranges (3.8-4.2 for cysteine, 4.8-5.2 for lysine) that maximize killing activity while maintaining an acceptable therapeutic index. This resolves the contradiction by finding the optimal numerical value that balances productivity and harmful effects
Solution Approach 2:
The patent uses a specially designed linker as an intermediary between the antibody and cytotoxin. The linker controls the release mechanism and timing of the toxin, allowing high killing activity at the tumor site while reducing systemic toxicity, thus resolving the contradiction between productivity and harmful factors
3Adaptability or versatility
If different types of toxins are used to target various tumor cells, then the adaptability to different tumors is improved, but the manufacturing precision and stability decrease
Solution Approach 1:
The patent creates a universal ADC platform where a single validated anti-CD39 antibody can be combined with multiple different linker-toxin modules to treat various CD39-expressing tumors. This multi-functional approach provides adaptability to different tumor types while maintaining manufacturing precision through standardized conjugation protocols
Solution Approach 2:
The patent segments the ADC into distinct functional modules (antibody, linker, toxin) that can be independently optimized and combined. This modular segmentation allows systematic exploration of different toxin types while maintaining consistent, precise manufacturing of each module and their standardized assembly
Data Source
AI summary
The present invention provides an anti-CD39 antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition comprising the conjugate or the pharmaceutically acceptable salt or solvate thereof, and use thereof as an anti-cancer drug, particularly use thereof in the preparation of a medicament for treating a CD39-mediated disease or disorder. The anti-CD39 antibody-drug conjugate provided by the present application significantly improves the effects and in-vivo/in-vitro tumor-killing activity of cytotoxin drugs.